A Comparison of Inflammatory Mediators Surrounding Titanium or Zirconium Implant Abutments

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

46 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-12-31

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether there are differences in inflammatory markers and bone-mediator protein expression in the fluid surrounding implant abutments manufactured with either titanium or zirconium.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Periimplant Mucosa Dynamics Around Divergent and Concave Atlantis Abutment Transition Profiles

NCT01871220

Dental Implant, Single-Tooth Esthetics, Dental

COMPLETED NA

Dental Implant Study Comparing Two Types of Metals Used for Dental Implants

NCT01714024

Tooth Replacement

COMPLETED NA

Clinical Outcome of Two-piece Zirconia Implants in Immediate Implant Placement

NCT05369299

Immediate Implantation of Two-piece Zirconia Dental Implants

COMPLETED NA

An Exploratory Clinical Investigation Evaluating Two Abutment Surfaces

NCT06557447

Peri-implant Crevicular Fluid

NOT_YET_RECRUITING NA

Surgical Treatment of Peri-implantitis

NCT03163602

Peri-Implantitis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this cross-sectional study is to utilize the paper strip-based peri-implant crevicular fluid (PICF) sampling technique to evaluate the influence that transmucosal abutment biomaterials of either titanium or zirconium oxide, which have been in situ for greater than six months, have in the expression of specific pro-inflammatory and bone-mediators.

Subjects who had previously undergone single-tooth implant replacement therapy are invited to participate and informed consent is obtained.

All participants receive a clinical and radiographic exam of the implant site that is sampled for PICF. Clinical and radiographic parameters such as implant mobility, presence or absence of supragingival plaque, and interproximal bone levels were assessed. Peri-apical radiographs, utilizing a paralleling technique, will be obtained from each implant fixture to evaluate the marginal bone level compared to baseline periapical radiographs made at the time of definitive prosthesis delivery. Each participant's implant site is isolated with cotton rolls, light air is applied over the site to eliminate the potential for ambient salivary contamination of the PICF sample. The implant site is sampled for 30 seconds at four distinct sites (mesio-buccal, disto-buccal, mesio-lingual, disto-lingual) by one clinician under loupe magnification. The fluid volumes collected on each strip will be quantified using the Periotron 8000 Instrument.

Cytokine, chemokine, and bone mediator quantities (pg/30 s) were determined using a commercial 22-multiplexed fluorescent bead-based immunoassay. Two specific multiplex kits are utilized (Milliplex MAP Human cytokine/Chemokine Immunoassay \& Milliplex MAP Human Bone Panel 1B Immunoassay).

Biostatisticians are masked to the implant abutment biomaterial designations (masked as "A" and "B") during data analysis. Initial bivariate analysis using the Wilcoxon-Mann-Whitney (Wilcoxon Rank Sum) test will be employed to assess the difference in distribution between the two groups (titanium dioxide or zirconium oxide) for each cytokine/bone mediator and for age. The same approach is used to consider whether a gender difference was associated with a particular cytokine/bone mediator. Gender distribution in the two groups will be compared using the Fisher exact test. The Spearman rank correlation will be used to assess the possibility of a relationship with age for each cytokine. Rank-based regression models will be used to adjust for possible effects of age and gender for both cytokine and bone mediator levels.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peri-implantitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Titanium Implant Abutments

Gingival Crevicular Fluid Sampling

Intervention Type PROCEDURE

Gingival crevicular fluids will be sampled from single implant restorations that have been in function for at least 6 months

Zirconium Implant Abutments

Gingival Crevicular Fluid Sampling

Intervention Type PROCEDURE

Gingival crevicular fluids will be sampled from single implant restorations that have been in function for at least 6 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gingival Crevicular Fluid Sampling

Gingival crevicular fluids will be sampled from single implant restorations that have been in function for at least 6 months

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* presence of a single-tooth implant-supported restoration bounded by natural teeth in stable occlusion
* pre-fabricated or computer aided design and computer aided manufactured (CAD/CAM) transmucosal abutments of either commercially-pure titanium dioxide or zirconium dioxide
* a minimum of 6 months of clinical function in situ.